Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158

1.

Single-Cell Lymphocyte Heterogeneity in Advanced Cutaneous T-cell Lymphoma Skin Tumors.

Gaydosik AM, Tabib T, Geskin LJ, Bayan CA, Conway JF, Lafyatis R, Fuschiotti P.

Clin Cancer Res. 2019 Apr 22. doi: 10.1158/1078-0432.CCR-19-0148. [Epub ahead of print]

PMID:
31010835
2.

A Bayesian mixture model for clustering droplet-based single-cell transcriptomic data from population studies.

Sun Z, Chen L, Xin H, Jiang Y, Huang Q, Cillo AR, Tabib T, Kolls JK, Bruno TC, Lafyatis R, Vignali DAA, Chen K, Ding Y, Hu M, Chen W.

Nat Commun. 2019 Apr 9;10(1):1649. doi: 10.1038/s41467-019-09639-3.

3.

Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion.

Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, Pennathur A, Corry DB, Luketich JD, Lafyatis R, Chen W, Poholek AC, Bruno TC, Workman CJ, Vignali DAA.

Nat Immunol. 2019 Jun;20(6):724-735. doi: 10.1038/s41590-019-0346-9. Epub 2019 Apr 1.

PMID:
30936494
4.

Perivascular Adventitial Fibroblast Specialization Accompanies T Cell Retention in the Inflamed Human Dermis.

Barron AMS, Mantero JC, Ho JD, Nazari B, Horback KL, Bhawan J, Lafyatis R, Lam C, Browning JL.

J Immunol. 2019 Jan 1;202(1):56-68. doi: 10.4049/jimmunol.1801209. Epub 2018 Dec 3.

5.

Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease.

Moll M, Christmann RB, Zhang Y, Whitfield ML, Wang YM, Rice L, Stratton E, Lafyatis R, Farber HW.

J Scleroderma Relat Disord. 2018 Oct;3(3):242-248. doi: 10.1177/2397198318764780. Epub 2018 Mar 22.

6.

Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin.

Apostolidis SA, Stifano G, Tabib T, Rice LM, Morse CM, Kahaleh B, Lafyatis R.

Front Immunol. 2018 Oct 1;9:2191. doi: 10.3389/fimmu.2018.02191. eCollection 2018.

7.

Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial.

Mantero JC, Kishore N, Ziemek J, Stifano G, Zammitti C, Khanna D, Gordon JK, Spiera R, Zhang Y, Simms RW, Lafyatis R.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):146-149. Epub 2018 Sep 30.

PMID:
30277862
8.

Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.

Stifano G, Sornasse T, Rice LM, Na L, Chen-Harris H, Khanna D, Jahreis A, Zhang Y, Siegel J, Lafyatis R.

Arthritis Rheumatol. 2018 Jun;70(6):912-919. doi: 10.1002/art.40455.

9.

Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.

Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, Khanna D, Jahreis A, Siegel J, Sornasse T.

Ann Rheum Dis. 2018 Sep;77(9):1362-1371. doi: 10.1136/annrheumdis-2018-213031. Epub 2018 May 31.

10.

Gene-level association analysis of systemic sclerosis: A comparison of African-Americans and White populations.

Gorlova OY, Li Y, Gorlov I, Ying J, Chen WV, Assassi S, Reveille JD, Arnett FC, Zhou X, Bossini-Castillo L, Lopez-Isac E, Acosta-Herrera M, Gregersen PK, Lee AT, Steen VD, Fessler BJ, Khanna D, Schiopu E, Silver RM, Molitor JA, Furst DE, Kafaja S, Simms RW, Lafyatis RA, Carreira P, Simeon CP, Castellvi I, Beltran E, Ortego N, Amos CI, Martin J, Mayes MD.

PLoS One. 2018 Jan 2;13(1):e0189498. doi: 10.1371/journal.pone.0189498. eCollection 2018.

11.

Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis.

Fleury M, Belkina AC, Proctor EA, Zammitti C, Simms RW, Lauffenburger DA, Snyder-Cappione JE, Lafyatis R, Dooms H.

Arthritis Rheumatol. 2018 Apr;70(4):566-577. doi: 10.1002/art.40399. Epub 2018 Mar 7.

12.

14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in TC2 and CD8+ lymphocytes from patients with scleroderma.

Cascio S, Medsger TA Jr, Hawse WF, Watkins SC, Milcarek C, Moreland LW, Lafyatis RA, Fuschiotti P.

J Allergy Clin Immunol. 2018 Jul;142(1):109-119.e6. doi: 10.1016/j.jaci.2017.10.029. Epub 2017 Nov 15.

PMID:
29155097
13.

SFRP2/DPP4 and FMO1/LSP1 Define Major Fibroblast Populations in Human Skin.

Tabib T, Morse C, Wang T, Chen W, Lafyatis R.

J Invest Dermatol. 2018 Apr;138(4):802-810. doi: 10.1016/j.jid.2017.09.045. Epub 2017 Dec 6. Erratum in: J Invest Dermatol. 2018 Sep;138(9):2086.

14.

DIMM-SC: a Dirichlet mixture model for clustering droplet-based single cell transcriptomic data.

Sun Z, Wang T, Deng K, Wang XF, Lafyatis R, Ding Y, Hu M, Chen W.

Bioinformatics. 2018 Jan 1;34(1):139-146. doi: 10.1093/bioinformatics/btx490.

15.

Inhibition of β-Catenin Signaling in the Skin Rescues Cutaneous Adipogenesis in Systemic Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial of C-82.

Lafyatis R, Mantero JC, Gordon J, Kishore N, Carns M, Dittrich H, Spiera R, Simms RW, Varga J.

J Invest Dermatol. 2017 Dec;137(12):2473-2483. doi: 10.1016/j.jid.2017.06.032. Epub 2017 Aug 12.

16.

Limited cutaneous systemic sclerosis skin demonstrates distinct molecular subsets separated by a cardiovascular development gene expression signature.

Derrett-Smith EC, Martyanov V, Chighizola CB, Moinzadeh P, Campochiaro C, Khan K, Wood TA, Meroni PL, Abraham DJ, Ong VH, Lafyatis R, Whitfield ML, Denton CP.

Arthritis Res Ther. 2017 Jul 4;19(1):156. doi: 10.1186/s13075-017-1360-7.

17.
18.

Blockade of PDGF Receptors by Crenolanib Has Therapeutic Effect in Patient Fibroblasts and in Preclinical Models of Systemic Sclerosis.

Makino K, Makino T, Stawski L, Mantero JC, Lafyatis R, Simms R, Trojanowska M.

J Invest Dermatol. 2017 Aug;137(8):1671-1681. doi: 10.1016/j.jid.2017.03.032. Epub 2017 Apr 19.

19.

A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis.

Taroni JN, Greene CS, Martyanov V, Wood TA, Christmann RB, Farber HW, Lafyatis RA, Denton CP, Hinchcliff ME, Pioli PA, Mahoney JM, Whitfield ML.

Genome Med. 2017 Mar 23;9(1):27. doi: 10.1186/s13073-017-0417-1.

20.

Stretching Reduces Skin Thickness and Improves Subcutaneous Tissue Mobility in a Murine Model of Systemic Sclerosis.

Xiong Y, Berrueta L, Urso K, Olenich S, Muskaj I, Badger GJ, Aliprantis A, Lafyatis R, Langevin HM.

Front Immunol. 2017 Feb 16;8:124. doi: 10.3389/fimmu.2017.00124. eCollection 2017.

21.

Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis.

Man A, Correa JK, Ziemek J, Simms RW, Felson DT, Lafyatis R.

Ann Rheum Dis. 2017 Aug;76(8):1374-1380. doi: 10.1136/annrheumdis-2016-210534. Epub 2017 Feb 17.

PMID:
28213563
22.

Skin-Resident Effector Memory CD8+CD28- T Cells Exhibit a Profibrotic Phenotype in Patients with Systemic Sclerosis.

Li G, Larregina AT, Domsic RT, Stolz DB, Medsger TA Jr, Lafyatis R, Fuschiotti P.

J Invest Dermatol. 2017 May;137(5):1042-1050. doi: 10.1016/j.jid.2016.11.037. Epub 2016 Dec 22.

23.

TRPV4 ION Channel Is Associated with Scleroderma.

Goswami R, Cohen J, Sharma S, Zhang DX, Lafyatis R, Bhawan J, Rahaman SO.

J Invest Dermatol. 2017 Apr;137(4):962-965. doi: 10.1016/j.jid.2016.10.045. Epub 2016 Nov 23. No abstract available.

24.

Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis.

Chia JJ, Zhu T, Chyou S, Dasoveanu DC, Carballo C, Tian S, Magro CM, Rodeo S, Spiera RF, Ruddle NH, McGraw TE, Browning JL, Lafyatis R, Gordon JK, Lu TT.

J Clin Invest. 2016 Nov 1;126(11):4331-4345. doi: 10.1172/JCI85740. Epub 2016 Oct 10.

25.

Pristane-Accelerated Autoimmune Disease in (SWR X NZB) F1 Mice Leads to Prominent Tubulointerstitial Inflammation and Human Lupus Nephritis-Like Fibrosis.

Gardet A, Chou WC, Reynolds TL, Velez DB, Fu K, Czerkowicz JM, Bajko J, Ranger AM, Allaire N, Kerns HM, Ryan S, Legault HM, Dunstan RW, Lafyatis R, Lukashev M, Viney JL, Browning JL, Rabah D.

PLoS One. 2016 Oct 19;11(10):e0164423. doi: 10.1371/journal.pone.0164423. eCollection 2016.

26.

A Proteome-Derived Longitudinal Pharmacodynamic Biomarker for Diffuse Systemic Sclerosis Skin.

Rice LM, Mantero JC, Stifano G, Ziemek J, Simms RW, Gordon J, Domsic R, Lafyatis R.

J Invest Dermatol. 2017 Jan;137(1):62-70. doi: 10.1016/j.jid.2016.08.027. Epub 2016 Sep 14.

27.

Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90.

Nazari B, Rice LM, Stifano G, Barron AM, Wang YM, Korndorf T, Lee J, Bhawan J, Lafyatis R, Browning JL.

Am J Pathol. 2016 Oct;186(10):2650-64. doi: 10.1016/j.ajpath.2016.06.020. Epub 2016 Aug 23.

28.

IL4RA on lymphatic endothelial cells promotes T cell egress during sclerodermatous graft versus host disease.

Urso K, Alvarez D, Cremasco V, Tsang K, Grauel A, Lafyatis R, von Andrian UH, Ermann J, Aliprantis AO.

JCI Insight. 2016 Aug 4;1(12). pii: e88057.

29.

Editorial: Epigenetics in Systemic Sclerosis.

Lafyatis R.

Arthritis Rheumatol. 2016 Dec;68(12):2841-2844. doi: 10.1002/art.39830. No abstract available.

30.

Low heme oxygenase-1 levels in patients with systemic sclerosis are associated with an altered Toll-like receptor response: another role for CXCL4?

van Bon L, Cossu M, Scharstuhl A, Pennings BW, Vonk MC, Vreman HJ, Lafyatis RL, van den Berg W, Wagener FA, Radstake TR.

Rheumatology (Oxford). 2016 Nov;55(11):2066-2073. Epub 2016 Jul 13.

PMID:
27411481
31.

An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.

Castelino FV, Bain G, Pace VA, Black KE, George L, Probst CK, Goulet L, Lafyatis R, Tager AM.

Arthritis Rheumatol. 2016 Dec;68(12):2964-2974. doi: 10.1002/art.39797.

32.

miR-155 in the progression of lung fibrosis in systemic sclerosis.

Christmann RB, Wooten A, Sampaio-Barros P, Borges CL, Carvalho CR, Kairalla RA, Feghali-Bostwick C, Ziemek J, Mei Y, Goummih S, Tan J, Alvarez D, Kass DJ, Rojas M, de Mattos TL, Parra E, Stifano G, Capelozzi VL, Simms RW, Lafyatis R.

Arthritis Res Ther. 2016 Jul 5;18(1):155. doi: 10.1186/s13075-016-1054-6.

33.

Tenascin-C drives persistence of organ fibrosis.

Bhattacharyya S, Wang W, Morales-Nebreda L, Feng G, Wu M, Zhou X, Lafyatis R, Lee J, Hinchcliff M, Feghali-Bostwick C, Lakota K, Budinger GR, Raparia K, Tamaki Z, Varga J.

Nat Commun. 2016 Jun 3;7:11703. doi: 10.1038/ncomms11703.

34.

Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.

Khanna D, Denton CP, Jahreis A, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Lafyatis R, Stifano G, Spotswood H, Chen-Harris H, Dziadek S, Morimoto A, Sornasse T, Siegel J, Furst DE.

Lancet. 2016 Jun 25;387(10038):2630-2640. doi: 10.1016/S0140-6736(16)00232-4. Epub 2016 May 5. Erratum in: Lancet. 2018 Apr 7;391(10128):1356.

PMID:
27156934
35.

Identification of Optimal Mouse Models of Systemic Sclerosis by Interspecies Comparative Genomics.

Sargent JL, Li Z, Aliprantis AO, Greenblatt M, Lemaire R, Wu MH, Wei J, Taroni J, Harris A, Long KB, Burgwin C, Artlett CM, Blankenhorn EP, Lafyatis R, Varga J, Clark SH, Whitfield ML.

Arthritis Rheumatol. 2016 Aug;68(8):2003-15. doi: 10.1002/art.39658.

36.

The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis.

Ziemek J, Man A, Hinchcliff M, Varga J, Simms RW, Lafyatis R.

Rheumatology (Oxford). 2016 May;55(5):911-7. doi: 10.1093/rheumatology/kew003. Epub 2016 Feb 15.

37.

Stress granules and RNA processing bodies are novel autoantibody targets in systemic sclerosis.

Johnson ME, Grassetti AV, Taroni JN, Lyons SM, Schweppe D, Gordon JK, Spiera RF, Lafyatis R, Anderson PJ, Gerber SA, Whitfield ML.

Arthritis Res Ther. 2016 Jan 22;18:27. doi: 10.1186/s13075-016-0914-4.

38.

The HLA-B*35 allele modulates ER stress, inflammation and proliferation in PBMCs from Limited Cutaneous Systemic Sclerosis patients.

Lenna S, Assassi S, Farina GA, Mantero JC, Scorza R, Lafyatis R, Farber HW, Trojanowska M.

Arthritis Res Ther. 2015 Dec 16;17:363. doi: 10.1186/s13075-015-0881-1.

39.

Resolution of Skin Fibrosis by Neutralization of the Antifibrinolytic Function of Plasminogen Activator Inhibitor 1.

Lemaire R, Burwell T, Sun H, Delaney T, Bakken J, Cheng L, Rebelatto MC, Czapiga M, de-Mendez I, Coyle AJ, Herbst R, Lafyatis R, Connor J.

Arthritis Rheumatol. 2016 Feb;68(2):473-83. doi: 10.1002/art.39443.

40.

Local skin gene expression reflects both local and systemic skin disease in patients with systemic sclerosis.

Rice LM, Stifano G, Ziemek J, Lafyatis R.

Rheumatology (Oxford). 2016 Feb;55(2):377-9. doi: 10.1093/rheumatology/kev335. Epub 2015 Sep 5. No abstract available.

41.

Promotion of Inflammatory Arthritis by Interferon Regulatory Factor 5 in a Mouse Model.

Duffau P, Menn-Josephy H, Cuda CM, Dominguez S, Aprahamian TR, Watkins AA, Yasuda K, Monach P, Lafyatis R, Rice LM, Kenneth Haines G 3rd, Gravallese EM, Baum R, Richez C, Perlman H, Bonegio RG, Rifkin IR.

Arthritis Rheumatol. 2015 Dec;67(12):3146-57. doi: 10.1002/art.39321.

42.

A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis.

Rice LM, Ziemek J, Stratton EA, McLaughlin SR, Padilla CM, Mathes AL, Christmann RB, Stifano G, Browning JL, Whitfield ML, Spiera RF, Gordon JK, Simms RW, Zhang Y, Lafyatis R.

Arthritis Rheumatol. 2015 Nov;67(11):3004-15. doi: 10.1002/art.39287.

43.

Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.

Rice LM, Padilla CM, McLaughlin SR, Mathes A, Ziemek J, Goummih S, Nakerakanti S, York M, Farina G, Whitfield ML, Spiera RF, Christmann RB, Gordon JK, Weinberg J, Simms RW, Lafyatis R.

J Clin Invest. 2015 Jul 1;125(7):2795-807. doi: 10.1172/JCI77958. Epub 2015 Jun 22.

44.

A Role of Myocardin Related Transcription Factor-A (MRTF-A) in Scleroderma Related Fibrosis.

Shiwen X, Stratton R, Nikitorowicz-Buniak J, Ahmed-Abdi B, Ponticos M, Denton C, Abraham D, Takahashi A, Suki B, Layne MD, Lafyatis R, Smith BD.

PLoS One. 2015 May 8;10(5):e0126015. doi: 10.1371/journal.pone.0126015. eCollection 2015.

45.

CpGB DNA activates dermal macrophages and specifically recruits inflammatory monocytes into the skin.

Mathes AL, Rice L, Affandi AJ, DiMarzio M, Rifkin IR, Stifano G, Christmann RB, Lafyatis R.

Exp Dermatol. 2015 Feb;24(2):133-9. doi: 10.1111/exd.12603. Epub 2015 Jan 12.

46.

Sustained β-catenin activity in dermal fibroblasts promotes fibrosis by up-regulating expression of extracellular matrix protein-coding genes.

Hamburg-Shields E, DiNuoscio GJ, Mullin NK, Lafyatis R, Atit RP.

J Pathol. 2015 Apr;235(5):686-97. doi: 10.1002/path.4481. Epub 2015 Jan 7.

47.

Transforming growth factor β--at the centre of systemic sclerosis.

Lafyatis R.

Nat Rev Rheumatol. 2014 Dec;10(12):706-19. doi: 10.1038/nrrheum.2014.137. Epub 2014 Aug 19. Review.

PMID:
25136781
48.

Chronic Toll-like receptor 4 stimulation in skin induces inflammation, macrophage activation, transforming growth factor beta signature gene expression, and fibrosis.

Stifano G, Affandi AJ, Mathes AL, Rice LM, Nakerakanti S, Nazari B, Lee J, Christmann RB, Lafyatis R.

Arthritis Res Ther. 2014 Jul 1;16(4):R136. doi: 10.1186/ar4598.

49.

Identification of cadherin 11 as a mediator of dermal fibrosis and possible role in systemic sclerosis.

Wu M, Pedroza M, Lafyatis R, George AT, Mayes MD, Assassi S, Tan FK, Brenner MB, Agarwal SK.

Arthritis Rheumatol. 2014 Apr;66(4):1010-21. doi: 10.1002/art.38275.

50.

High Rhodotorula sequences in skin transcriptome of patients with diffuse systemic sclerosis.

Arron ST, Dimon MT, Li Z, Johnson ME, Wood TA, Feeney L, Angeles JG, Lafyatis R, Whitfield ML.

J Invest Dermatol. 2014 Aug;134(8):2138-2145. doi: 10.1038/jid.2014.127. Epub 2014 Mar 7.

Supplemental Content

Loading ...
Support Center